{"id":24305,"date":"2024-05-13T16:11:52","date_gmt":"2024-05-13T14:11:52","guid":{"rendered":"https:\/\/ggba.swiss\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/"},"modified":"2024-05-13T16:14:52","modified_gmt":"2024-05-13T14:14:52","slug":"ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/","title":{"rendered":"AC Immune et Takeda signent un accord de USD 100 millions pour soigner la maladie d’Alzheimer"},"content":{"rendered":"\n

La soci\u00e9t\u00e9 biopharmaceutique lausannoise AC Immune<\/a> et le g\u00e9ant pharmaceutique japonais Takeda<\/a> ont annonc\u00e9 la conclusion d’un accord exclusif d’option et de licence portant sur les droits mondiaux de l’ACI-24.060, une immunoth\u00e9rapie active prometteuse visant \u00e0 lutter contre la progression de la maladie d’Alzheimer.<\/p>\n\n\n\n

AC Immune, dont le si\u00e8ge se trouve \u00e0 l’EPFL Innovation Park<\/a>, a d\u00e9velopp\u00e9 ACI-24.060, un candidat innovant con\u00e7u pour cibler et neutraliser les formes toxiques de l’amylo\u00efde b\u00eata (Abeta) – des prot\u00e9ines consid\u00e9r\u00e9es comme des contributeurs cl\u00e9s \u00e0 la formation des plaques neuronales associ\u00e9es \u00e0 la maladie d’Alzheimer. L’essai clinique de phase 1b\/2 ABATE en cours \u00e9value le potentiel d’ACI-24.060 chez des patients atteints d’une maladie d’Alzheimer prodromique et des adultes atteints du syndrome de Down, en se concentrant sur sa s\u00e9curit\u00e9, sa tol\u00e9rabilit\u00e9 et son efficacit\u00e9 \u00e0 pr\u00e9venir l’accumulation de plaques et \u00e0 favoriser l’\u00e9limination des plaques dans le cerveau.<\/p>\n\n\n\n

Dans le communiqu\u00e9 de presse de la soci\u00e9t\u00e9, la Dr Andrea Pfeifer, CEO d’AC Immune, a soulign\u00e9 l’importance de cette collaboration avec Takeda, en insistant sur le potentiel de l’ACI-24.060 \u00e0 red\u00e9finir le traitement de la maladie d’Alzheimer. \u00ab En tant que pionniers de l’immunoth\u00e9rapie active, le partenariat avec Takeda \u00e0 cette phase cruciale du d\u00e9veloppement nous permet de tirer parti de leur vaste expertise et de leurs ressources pour lancer des essais complets de phase 3 \u00bb, a-t-elle d\u00e9clar\u00e9.<\/p>\n\n\n\n

Selon les termes de l’accord, AC Immune recevra de Takeda un paiement initial de USD 100 millions, avec la possibilit\u00e9 de paiements \u00e9chelonn\u00e9s suppl\u00e9mentaires qui pourraient s’\u00e9lever \u00e0 un total d’environ USD 2,1 milliards. Takeda prendra en charge la poursuite du d\u00e9veloppement clinique, les activit\u00e9s r\u00e9glementaires et la commercialisation mondiale apr\u00e8s l’exercice de l’option.<\/p>\n\n\n\n

Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit chez Takeda, a exprim\u00e9 son enthousiasme pour ce partenariat, soulignant l’approche innovante du traitement et son potentiel \u00e0 avoir un impact significatif sur les personnes souffrant de la maladie d’Alzheimer. \u00ab Cet accord associe notre profonde expertise en neurosciences \u00e0 la technologie d’immunoth\u00e9rapie r\u00e9volutionnaire d’AC Immune, renfor\u00e7ant ainsi notre engagement \u00e0 r\u00e9pondre aux besoins critiques en mati\u00e8re de traitement de la maladie d’Alzheimer \u00bb, a-t-elle d\u00e9clar\u00e9.<\/p>\n\n\n\n

Cette collaboration strat\u00e9gique t\u00e9moigne non seulement des capacit\u00e9s d’innovation d’AC Immune, d\u00e9montr\u00e9es par ses plateformes technologiques SupraAntigen\u00ae et Morphomer\u00ae, mais s’inscrit \u00e9galement dans la mission de Takeda de promouvoir de nouvelles approches th\u00e9rapeutiques dans ses principaux domaines d’activit\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"

Takeda recevra une option exclusive de licence pour l’ACI-24.060 d’AC Immune, une th\u00e9rapie r\u00e9volutionnaire pour combattre la progression de la maladie d’Alzheimer, pour un paiement initial de USD 100 millions et des versements \u00e9chelonn\u00e9s potentiels de USD 2,1 milliards.<\/p>\n","protected":false},"author":6,"featured_media":24302,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1141,1171,1142],"class_list":["post-24305","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-personalized-medicine-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"\nAC Immune et Takeda signent un accord de USD 100 millions<\/title>\n<meta name=\"description\" content=\"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune et Takeda signent un accord de USD 100 millions\" \/>\n<meta property=\"og:description\" content=\"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-13T14:11:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-13T14:14:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune et Takeda signent un accord de USD 100 millions pour soigner la maladie d’Alzheimer\",\"datePublished\":\"2024-05-13T14:11:52+00:00\",\"dateModified\":\"2024-05-13T14:14:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\"},\"wordCount\":459,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"keywords\":[\"Personalized Medicine\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\",\"name\":\"AC Immune et Takeda signent un accord de USD 100 millions\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"datePublished\":\"2024-05-13T14:11:52+00:00\",\"dateModified\":\"2024-05-13T14:14:52+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"Le partenariat entre AC Immune et Takeda marque une avanc\u00e9e d\u00e9cisive dans la qu\u00eate d'un nouvel espoir pour les millions de personnes touch\u00e9es par la maladie d'Alzheimer dans le monde.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune et Takeda signent un accord de USD 100 millions pour soigner la maladie d’Alzheimer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune et Takeda signent un accord de USD 100 millions","description":"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/","og_locale":"fr_FR","og_type":"article","og_title":"AC Immune et Takeda signent un accord de USD 100 millions","og_description":"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.","og_url":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-05-13T14:11:52+00:00","article_modified_time":"2024-05-13T14:14:52+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune et Takeda signent un accord de USD 100 millions pour soigner la maladie d’Alzheimer","datePublished":"2024-05-13T14:11:52+00:00","dateModified":"2024-05-13T14:14:52+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/"},"wordCount":459,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","keywords":["Personalized Medicine","Pharma","R&D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/","url":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/","name":"AC Immune et Takeda signent un accord de USD 100 millions","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","datePublished":"2024-05-13T14:11:52+00:00","dateModified":"2024-05-13T14:14:52+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Takeda recevra une option exclusive de licence pour l'ACI-24.060 d'AC Immune pour un paiement initial de USD 100 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Takeda-AC-Immune-Alzheimer-2360x1622-1.jpeg","width":2360,"height":1622,"caption":"Le partenariat entre AC Immune et Takeda marque une avanc\u00e9e d\u00e9cisive dans la qu\u00eate d'un nouvel espoir pour les millions de personnes touch\u00e9es par la maladie d'Alzheimer dans le monde."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ac-immune-et-takeda-signent-un-accord-de-usd-100-millions-pour-soigner-la-maladie-dalzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AC Immune et Takeda signent un accord de USD 100 millions pour soigner la maladie d’Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=24305"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24305\/revisions"}],"predecessor-version":[{"id":24307,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24305\/revisions\/24307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/24302"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=24305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=24305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=24305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}